Alcon acquires ophthalmic division

Article

Alcon will acquire the ophthalmic division of SensoMotoric Instruments (SMI).

Alcon will acquire the ophthalmic division of SensoMotoric Instruments (SMI).

SMI, a private company based in Germany, deals with ocular guidance technology such as real-time eye tracking, automatic registration of ocular imaging and IOL positing and alignment guidance.

Alcon will integrate SMI into its existing global cataract portfolio and will further develop existing products that improve patient outcomes in cataract surgery. This includes the IOL used to treat cataracts and correct refractive errors such as astigmatism and presbyopia.

Sabri Markabi, Senior Vice President of Research and Development at Alcon, commented, "This acquisition further strengthens Alcon's position in the cataract surgery market with an expansion into leading ocular tracking technology. The stare-of-the-art guidance technology provides surgeons with customization options and automated solutions, enabling optimal outcomes for their cataract patients including underlying refractive conditions."

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
© 2025 MJH Life Sciences

All rights reserved.